Download PDF
Semin Vasc Med 2004; 4(4): 401-406
DOI: 10.1055/s-2004-869597
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Statins and Cardiac Allograft Vasculopathy after Heart Transplantation

Jon A. Kobashigawa1 , 2
  • 1The David Geffen School of Medicine at the University of California at Los Angeles
  • 2University of California at Los Angeles Heart Transplant Program, University of California at Los Angeles, Los Angeles, California
Further Information

Publication History

Publication Date:
29 April 2005 (online)

    Permissions and Reprints

ABSTRACT

Coronary artery disease in the transplanted heart, also known as cardiac allograft vasculopathy, is one of the major causes of mortality late after heart transplantation. There are multiple immune and nonimmune risk factors associated with this disease process, one of which is hyperlipidemia. Use of lipid-lowering agents, specifically 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) was initially reported to have outcomes benefit and possibly immunosuppressive effects in a single-center study of heart transplant recipients. Other subsequent studies have supported this beneficial effect. Hyperlipidemia is associated with immune activity, particularly with respect to oxidation-sensitive signaling pathways. By lowering lipids, statins can ameliorate this immune activity, but it has been a matter of contention as to whether statins have cholesterol-independent immune-modulating effects. In two recent papers, cholesterol-independent immune effects of statins have been reported, including repressed induction of major histocompatibility complex class II by interferon-gamma, and selective blocking of leukocyte function antigen 1, both of which reduce the activation of T lymphocytes. The clinical reports demonstrating outcomes benefits in heart transplant recipients and recent laboratory publications that report an immunomodulatory effect of statins provide a firm scientific rationale to support the routine use of statins in heart transplant patients.

KEYWORDS

Heart transplantation - cardiac allograft vasculopathy - statins - outcomes

REFERENCES

  • 1 Johnson M R. Transplant coronary disease: non-immunologic risk factors.  J Heart Lung Transplant. 1992;  11 S124-S132
    PubMedSearch in Google Scholar
  • 2 Valantine H. Role of lipids in allograft vascular disease: a multicenter study of intimal thickening detected by intravascular ultrasound.  J Heart Lung Transplant. 1995;  14 S234-S237
    PubMedSearch in Google Scholar
  • 3 Stamler J S, Vaughan D E, Rudd M A et al.. Frequency of hypercholesterolemia after cardiac transplantation.  Am J Cardiol. 1988;  62 1268-1272
    CrossrefPubMedSearch in Google Scholar
  • 4 Superko H R, Haskell W L, Di Ricco C D. Lipoprotein and hepatic lipase activity and high-density lipoprotein subclasses after cardiac transplantation.  Am J Cardiol. 1990;  66 1131-1134
    CrossrefPubMedSearch in Google Scholar
  • 5 Kobashigawa J A, Kasiske B L. Hyperlipidemia in solid organ transplantation.  Transplantation. 1997;  63 331-338
    PubMedSearch in Google Scholar
  • 6 Eich D, Thompson J A, Ko D J et al.. Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease.  J Heart Lung Transplant. 1991;  10 45-49
    PubMedSearch in Google Scholar
  • 7 Esper E, Glagov S, Karp R B et al.. Role of hypercholesterolemia in accelerated transplant coronary vasculopathy: results of surgical therapy with partial ileal bypass in rabbits undergoing heterotopic heart transplantation.  J Heart Lung Transplant. 1997;  16 420-435
    PubMedSearch in Google Scholar
  • 8 Kapadia S R, Nissen S E, Ziada K M et al.. Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study.  J Am Coll Cardiol. 2001;  38 206-213
    CrossrefPubMedSearch in Google Scholar
  • 9 Alonso D R, Starek P K, Minick C R. Studies on the pathogenesis of atheroarteriosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection and hypercholesterolemia.  Am J Pathol. 1977;  87 415-442
    PubMedSearch in Google Scholar
  • 10 Tanaka H, Sukhova G K, Libby P. Interaction of the allogeneic state and hypercholesterolemia in arterial lesion formation in experimental cardiac allografts.  Arterioscler Thromb. 1994;  14 734-745
    PubMedSearch in Google Scholar
  • 11 Raisanen-Sokolowski A, Tilly-Kiesi M, Ustinov J et al.. Hyperlipidemia accelerates allograft arteriosclerosis (chronic rejection) in the rat.  Arterioscler Thromb. 1994;  14 2032-2042
    PubMedSearch in Google Scholar
  • 12 Shepherd J, Cobbe S M, Ford I et al.. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.  N Engl J Med. 1995;  333 1301-1307
    CrossrefPubMedSearch in Google Scholar
  • 13 Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).  Lancet. 1994;  344 1383-1389
    PubMedSearch in Google Scholar
  • 14 Sacks F M, Pfeffer M A, Moye L A et al.. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.  N Engl J Med. 1996;  335 1001-1009
    CrossrefPubMedSearch in Google Scholar
  • 15 Ridker P M, Rifai N, Pfeffer M A et al.. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.  Circulation. 1998;  98 839-844
    PubMedSearch in Google Scholar
  • 16 Kobashigawa J A, Katznelson S, Laks H et al.. Effect of pravastatin on outcomes after cardiac transplantation.  N Engl J Med. 1995;  333 621-627
    PubMedSearch in Google Scholar
  • 17 Cutts J L, Scallen T J, Watson J, Bankhurst A D. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity.  J Cell Physiol. 1989;  139 550-557
    CrossrefPubMedSearch in Google Scholar
  • 18 Kobashigawa J, Moriguchi J, Cogert G et al.. 10-year results of the pravastatin randomized trial in heart transplant recipients.  J Heart Lung Transplant. 2004;  23 S115
    PubMedSearch in Google Scholar
  • 19 Wenke K, Meiser B, Thiery J et al.. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial.  Circulation. 1997;  96 1398-1402
    PubMedSearch in Google Scholar
  • 20 Wenke K, Meiser B, Thiery J et al.. Simvastatin initiated early after heart transplantation: 8-year prospective experience.  Circulation. 2003;  107 93-97
    CrossrefPubMedSearch in Google Scholar
  • 21 Weis M, Pehlivanli S, Meiser B M, von Scheidt W. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation.  J Am Coll Cardiol. 2001;  38 814-818
    CrossrefPubMedSearch in Google Scholar
  • 22 Ballantyne C M, Short B C, Bourge R C et al.. Lipid treatment and survival after heart transplantation.  J Am Coll Cardiol 31. 1998;  157
    PubMedSearch in Google Scholar
  • 23 Keogh A, Macdonald P, Kaan A, Aboyoun C, Spratt P, Mundy J. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation.  J Heart Lung Transplant. 2000;  19 529-537
    PubMedSearch in Google Scholar
  • 24 Mehra M R, Uber P A, Vivekananthan K et al.. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival.  J Am Coll Cardiol. 2002;  40 1609-1614
    CrossrefPubMedSearch in Google Scholar
  • 25 Akhlaghi F, Ashley J, Keogh A, Brown K. Cyclosporine plasm unbound fraction in heart and lung transplantation recipients.  Ther Drug Monit. 1999;  21 8-16
    CrossrefPubMedSearch in Google Scholar
  • 26 Regazzi M B, Iacona I, Campana C, Gavazzi A, Vigano M, Perani G. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporine A.  Transplant Proc. 1994;  26 2644-2645
    PubMedSearch in Google Scholar
  • 27 McPherson R, Tsoukas C, Baines M G et al.. Effects of lovastatin on natural killer cell function and other immunological parameters in man.  J Clin Immunol. 1993;  13 439-444
    CrossrefPubMedSearch in Google Scholar
  • 28 Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator.  Nat Med. 2000;  6 1399-1402
    CrossrefPubMedSearch in Google Scholar
  • 29 Weitz-Schmidt G, Welzenbach K, Brinkmann V et al.. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site.  Nat Med. 2001;  7 687-692
    PubMedSearch in Google Scholar
  • 30 Palinski W, Tsimikas S. Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis.  J Am Soc Nephrol. 2002;  13 1673-1681
    CrossrefPubMedSearch in Google Scholar
  • 31 Finkel T. Oxygen radicals and signaling.  Curr Opin Cell Biol. 1998;  10 248-253
    CrossrefPubMedSearch in Google Scholar
  • 32 Napoli C, de Nigris F, Palinski W. Multiple role of reactive oxygen species in the arterial wall.  J Cell Biochem. 2001;  82 674-682
    CrossrefPubMedSearch in Google Scholar
  • 33 Liao F, Andalibi A, Qiao J H, Allayee H, Fogelman A M, Lusis A J. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice.  J Clin Invest. 1994;  94 877-884
    PubMedSearch in Google Scholar
  • 34 Collins T, Cybulsky M I. NF-kappa B: pivotal mediator or innocent bystander in atherogenesis?.  J Clin Invest. 2001;  107 255-264
    CrossrefPubMedSearch in Google Scholar
  • 35 Sata M, Walsh K. Oxidized LDL activates fas-mediated endothelial cell apoptosis.  J Clin Invest. 1998;  102 1682-1689
    CrossrefPubMedSearch in Google Scholar
  • 36 Von Harsdorf R, Li P F, Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis.  Circulation. 1999;  99 2934-2941
    PubMedSearch in Google Scholar
  • 37 Napoli C, Quehenberger O, de Nigris F, Abete P, Glass C K, Palinski W. Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells.  FASEB J. 2000;  14 1996-2007
    CrossrefPubMedSearch in Google Scholar
  • 38 Jiang C, Ting A T, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.  Nature. 1998;  391 82-86
    CrossrefPubMedSearch in Google Scholar
  • 39 Nagy L, Tontonoz P, Alvarez J G, Chen H, Evans R M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-gamma.  Cell. 1998;  93 229-240
    CrossrefPubMedSearch in Google Scholar
  • 40 Li A C, Brown K K, Silvestre M J, Willson T M, Palinski W, Glass C K. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.  J Clin Invest. 2000;  106 523-531
    CrossrefPubMedSearch in Google Scholar
  • 41 Chawla A, Boisvert W A, Lee C H et al.. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis.  Mol Cell. 2001;  7 161-171
    CrossrefPubMedSearch in Google Scholar
  • 42 Downward J, Graves J D, Warne P H, Rayter S, Cantrell D A. Stimulation of p21ras upon T-cell activation.  Nature. 1990;  346 719-723
    CrossrefPubMedSearch in Google Scholar
  • 43 Casey P J. Protein lipidation in cell signaling.  Science. 1995;  268 221-225
    PubMedSearch in Google Scholar
  • 44 Ignarro L J, Cirino G, Casini A, Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview.  J Cardiovasc Pharmacol. 1999;  34 879-886
    CrossrefPubMedSearch in Google Scholar
  • 45 Davis K L, Martin E, Turko I V, Murad F. Novel effects of nitric oxide.  Annu Rev Pharmacol Toxicol. 2001;  41 203-236
    PubMedSearch in Google Scholar
  • 46 Laufs U, Liao J K. Direct vascular effects of HMG-CoA reductase inhibitors.  Trends Cardiovasc Med. 2000;  10 143-148
    CrossrefPubMedSearch in Google Scholar
  • 47 Guijarro C, Blanco-Colio L M, Ortego M et al.. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture.  Circ Res. 1998;  83 490-500
    PubMedSearch in Google Scholar
  • 48 Liu L, Moesner P, Kovach N L et al.. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s).  J Biol Chem. 1999;  274 33334-33340
    CrossrefPubMedSearch in Google Scholar
  • 49 Essig M, Nguyen G, Prie D, Escoubet B, Sraer J D, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins.  Circ Res. 1998;  83 683-690
    CrossrefPubMedSearch in Google Scholar
  • 50 Laufs U, Gertz K, Huang P et al.. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice.  Stroke. 2000;  31 2442-2449
    PubMedSearch in Google Scholar
  • 51 Wassmann S, Laufs U, Baumer A T et al.. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species.  Hypertension. 2001;  37 1450-1457
    PubMedSearch in Google Scholar
  • 52 Endres M, Laufs U, Huang Z et al.. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.  Proc Natl Acad Sci U S A. 1998;  95 8880-8885
    PubMedSearch in Google Scholar
  • 53 Laufs U, Liao J K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase.  J Biol Chem. 1998;  273 24266-24271
    CrossrefPubMedSearch in Google Scholar
  • 54 Wei X, Si M S, Imagawa D K, Ji P, Tromberg B J, Cahalan M D. Perillyl alcohol inhibits TCR-mediated [Ca(2 + )](i) signaling, alters cell shape and motility, and induces apoptosis in T lymphocytes.  Cell Immunol. 2000;  201 6-13
    CrossrefPubMedSearch in Google Scholar
  • 55 Si M S, Ji P, Tromberg B J et al.. Farnesyltransferase inhibition: a novel method of immunomodulation.  Int Immunopharmacol. 2003;  3 475-483
    PubMedSearch in Google Scholar
  • 56 Maggard M A, Johnson C, Wang T et al.. Inhibition of transplant vasculopathy is associated with attenuated host allo-antibody response.  Transplant Proc. 1999;  31 728-729
    CrossrefPubMedSearch in Google Scholar
  • 57 Rose E A, Smith C R, Petrossian G A, Barr M L, Reemtsma K. Humoral immune responses after cardiac transplantation: correlation with fatal rejection and graft atherosclerosis.  Surgery. 1989;  106 203-208
    PubMedSearch in Google Scholar
  • 58 Michaels P J, Espejo M L, Kobashigawa J et al.. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease.  J Heart Lung Transplant. 2003;  22 58-69
    PubMedSearch in Google Scholar
  • 59 Maggard M A, Ke B, Wang T et al.. Effects of pravastatin on chronic rejection of rat cardiac allografts.  Transplantation. 1998;  65 149-155
    PubMedSearch in Google Scholar

Jon A KobashigawaM.D. 

Division of Cardiology, University of California

Los Angeles, Medical Center, 100 UCLA Medical Plaza

#630, Los Angeles, California 90095